An "On Demand" canakinumab regimen for treating children with Colchicine-Resistant familial Mediterranean fever - A multicentre study
CONCLUSION: For individuals with crFMF, COD compared to CFF policy can achieve similar efficacy and safety, with a lower accumulated canakinumab dose, rendering it less immunosuppressive and less expensive.PMID:38569431 | DOI:10.1016/j.intimp.2024.111967 (Source: International Immunopharmacology)
Source: International Immunopharmacology - April 3, 2024 Category: Allergy & Immunology Authors: Katy Shehadeh Yoel Levinsky Shelly Kagan Tarek Zuabi Rotem Tal Neta Hana Aviran Yonatan Butbul Aviel Irit Tirosh Shiri Spielman Adi Miller-Barmak Rotem Semo Oz Liora Harel Gabriel Chodick Gil Amarilyo Source Type: research
Prednisolone Versus Colchicine for Acute Gout in Primary Care: statistical analysis plan for the pragmatic, multicenter, randomized, and double-blinded COPAGO non-inferiority trial
To date, colchicine and prednisolone are two effective therapies for the treatment of acute gout but have never been compared directly in a randomized clinical trial. In addition, in previous trials of treatin... (Source: Trials)
Source: Trials - April 3, 2024 Category: General Medicine Authors: Adrian Richter, Julia Truthmann, Eva Hummers, Julia Freyer Martins Pereira, Ildik ó Gágyor, Franziska Schuster, Amelie Witte, Susanne Böhm, Alexandra Greser, Petra Kamin, Sylvia Stracke, Marcus Dörr, Robin Bülow, Stefan Engeli, Jean François Chenot Tags: Update Source Type: research
Tobacco smoke condensate-induced senescence in endothelial cells was ameliorated by colchicine treatment via suppression of NF- κB and MAPKs P38 and ERK pathways activation
Smoking is the major cause of cardiovascular diseases and cancer. It induces oxidative stress, leading to DNA damage and cellular senescence. Senescent cells increase the expression and release of pro-inflamma... (Source: Cell Communication and Signaling)
Source: Cell Communication and Signaling - April 3, 2024 Category: Molecular Biology Authors: Dilaware Khan, Huakang Zhou, Jinliang You, Vera Annika Kaiser, Rajiv K Khajuria and Sajjad Muhammad Tags: Research Source Type: research
High systemic inflammation as a novel cardiovascular risk factor and target for anti-cytokine therapy: comment regarding the triglyceride glucose index
Int J Cardiovasc Imaging. 2024 Apr 1. doi: 10.1007/s10554-024-03046-6. Online ahead of print.ABSTRACTIn the last century, there has been more than enough research that proved the association of high lipid and glucose levels with cardiovascular disease, thus establishing the current well-known traditional cardiovascular risk factors such as dyslipidemia, diabetes, and metabolic syndrome. Hence, these cardiovascular risk factors are target therapy for glucose and lipid-lowering agents to prevent adverse cardiovascular events. However, despite controlling the lipid and glucose levels, some studies demonstrated the subclinical...
Source: Atherosclerosis - April 1, 2024 Category: Cardiology Authors: Artemio Garc ía-Escobar Rosa L ázaro-García Jos é-Ángel Cabrera Alfonso Jurado-Rom án Ra úl Moreno Source Type: research
High systemic inflammation as a novel cardiovascular risk factor and target for anti-cytokine therapy: comment regarding the triglyceride glucose index
AbstractIn the last century, there has been more than enough research that proved the association of high lipid and glucose levels with cardiovascular disease, thus establishing the current well-known traditional cardiovascular risk factors such as dyslipidemia, diabetes, and metabolic syndrome. Hence, these cardiovascular risk factors are target therapy for glucose and lipid-lowering agents to prevent adverse cardiovascular events. However, despite controlling the lipid and glucose levels, some studies demonstrated the subclinical atherosclerosis suggesting that these cardiovascular risk factors alone cannot account for t...
Source: The International Journal of Cardiovascular Imaging - April 1, 2024 Category: Radiology Source Type: research
Design, synthesis and biological evaluation of new 2,6-difluorinated phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new antimicrotubule agents
In this study, we evaluated the effect of the difluorination of the aromatic ring bearing the imidazolidin-2-one moiety (ring A) at positions 3, 5 and 2, 6 on their antiproliferative activity on four cancer cell lines, their ability to disrupt the microtubules and their toxicity toward chick embryos. We thus synthesized, characterized and biologically evaluated 24 new difluorinated PIB-SO derivatives designated as phenyl 3,5-difluoro-4-(2-oxoimidazolidin-1-yl)benzenesulfonates (3,5-PFB-SOs, 4-15) and phenyl 2,6-difluoro-4-(2-oxoimidazolidin-1-yl)benzenesulfonates (2,6-PFB-SOs, 16-27). The concentration of the drug required...
Source: Bioorganic Chemistry - March 28, 2024 Category: Chemistry Authors: Chahrazed Bouzriba Mathieu Gagn é-Boulet Atziri Corin Chavez Alvarez Vincent Ouellette Isabelle Laverdi ère S ébastien Fortin Source Type: research
Design, synthesis and biological evaluation of new 2,6-difluorinated phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new antimicrotubule agents
In this study, we evaluated the effect of the difluorination of the aromatic ring bearing the imidazolidin-2-one moiety (ring A) at positions 3, 5 and 2, 6 on their antiproliferative activity on four cancer cell lines, their ability to disrupt the microtubules and their toxicity toward chick embryos. We thus synthesized, characterized and biologically evaluated 24 new difluorinated PIB-SO derivatives designated as phenyl 3,5-difluoro-4-(2-oxoimidazolidin-1-yl)benzenesulfonates (3,5-PFB-SOs, 4-15) and phenyl 2,6-difluoro-4-(2-oxoimidazolidin-1-yl)benzenesulfonates (2,6-PFB-SOs, 16-27). The concentration of the drug required...
Source: Bioorganic Chemistry - March 28, 2024 Category: Chemistry Authors: Chahrazed Bouzriba Mathieu Gagn é-Boulet Atziri Corin Chavez Alvarez Vincent Ouellette Isabelle Laverdi ère S ébastien Fortin Source Type: research
Correction: Separable and Inseparable Silk Fibroin Microneedles for the Transdermal Delivery of Colchicine: Development, Characterization, and Comparisons
AAPS PharmSciTech. 2024 Mar 22;25(4):65. doi: 10.1208/s12249-024-02779-w.NO ABSTRACTPMID:38519629 | DOI:10.1208/s12249-024-02779-w (Source: AAPS PharmSciTech)
Source: AAPS PharmSciTech - March 23, 2024 Category: Drugs & Pharmacology Authors: Shiji Liao Guirong Qiu Yanping Hu Bohong Guo Yuqin Qiu Source Type: research
Correction: Separable and Inseparable Silk Fibroin Microneedles for the Transdermal Delivery of Colchicine: Development, Characterization, and Comparisons
AAPS PharmSciTech. 2024 Mar 22;25(4):65. doi: 10.1208/s12249-024-02779-w.NO ABSTRACTPMID:38519629 | DOI:10.1208/s12249-024-02779-w (Source: AAPS PharmSciTech)
Source: AAPS PharmSciTech - March 23, 2024 Category: Drugs & Pharmacology Authors: Shiji Liao Guirong Qiu Yanping Hu Bohong Guo Yuqin Qiu Source Type: research
Correction: Separable and Inseparable Silk Fibroin Microneedles for the Transdermal Delivery of Colchicine: Development, Characterization, and Comparisons
AAPS PharmSciTech. 2024 Mar 22;25(4):65. doi: 10.1208/s12249-024-02779-w.NO ABSTRACTPMID:38519629 | DOI:10.1208/s12249-024-02779-w (Source: AAPS PharmSciTech)
Source: AAPS PharmSciTech - March 23, 2024 Category: Drugs & Pharmacology Authors: Shiji Liao Guirong Qiu Yanping Hu Bohong Guo Yuqin Qiu Source Type: research
Correction: Separable and Inseparable Silk Fibroin Microneedles for the Transdermal Delivery of Colchicine: Development, Characterization, and Comparisons
AAPS PharmSciTech. 2024 Mar 22;25(4):65. doi: 10.1208/s12249-024-02779-w.NO ABSTRACTPMID:38519629 | DOI:10.1208/s12249-024-02779-w (Source: AAPS PharmSciTech)
Source: AAPS PharmSciTech - March 23, 2024 Category: Drugs & Pharmacology Authors: Shiji Liao Guirong Qiu Yanping Hu Bohong Guo Yuqin Qiu Source Type: research
Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Atherosclerosis - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Atherosclerosis - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
Role of Colchicine in Cardiovascular Disease Management
Arterioscler Thromb Vasc Biol. 2024 Mar 21. doi: 10.1161/ATVBAHA.124.319851. Online ahead of print.ABSTRACTColchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in extremely high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can even add to secondary prevention of major adverse cardiovascular events. As...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 21, 2024 Category: Cardiology Authors: Leo F Buckley Peter Libby Source Type: research
